How Miltenyi Hopes To Help Shape India’s CGT Landscape

 
• By Anju Ghangurde

Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.

Miltenyi leadership team
Standing (L-R): Sivakumar Natarajan, Commercial and Business Development Director, Miltenyi Biomedicine India; Dr Prudwidhar S, Medical Affairs Director, Miltenyi Biomedicine India. Seated: Dr Boris Stoffel, MD, Miltenyi Biotec B.V. & Co. KG and Priya Hingorani, MD, Miltenyi Biotec India and South East Asia

More from India

More from Advanced Therapies